Dr Sten Verland
Board of Directors
Pharmaceutical Sciences
OxThera AB
Sweden
Biography
Dr. Verland is a Partner of Sunstone Life Science Ventures and one of the three co-founders of Sunstone. Dr. Verland has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. Dr. Verland has played a key role in executing two M&As (Action Pharma and Zymenex). He currently serves on the Board of Directors of Orphazyme A/S, Rigontec GmbH, Vaximm AG, Anergis SA, Minervax APS and the Danish Venture Capital Association, as well as an observer to the Board of Directors of F2G Ltd. Dr. Verland holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen. Dr. Verland is a Partner of Sunstone Life Science Ventures and one of the three co-founders of Sunstone. Dr. Verland has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. Dr. Verland has played a key role in executing two M&As (Action Pharma and Zymenex). He currently serves on the Board of Directors of Orphazyme A/S, Rigontec GmbH, Vaximm AG, Anergis SA, Minervax APS and the Danish Venture Capital Association, as well as an observer to the Board of Directors of F2G Ltd. Dr. Verland holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen.
Research Interest
Pharmaceutical Sciences, Lipid Technologies, Pharmaceutical formulations etc.
